PPAR γ partial agonist, KR-62776, inhibits adipocyte differentiation via activation of ERK

J. Kim, D. C. Han, J. M. Kim, S. Y. Lee, S. J. Kim, J. R. Woo, J. W. Lee, S. K. Jung, K. S. Yoon, H. G. Cheon, S. S. Kim, S. H. Hong, B. M. Kwon

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Abstract

Indenone KR-62776 acts as an agonist of PPARγ without inducing obesity in animal models and cells. X-ray crystallography reveals that the indenone occupies the binding pocket in a different manner than rosiglitazone. 2-Dimensional gel-electrophoresis showed that the expression of 42 proteins was altered more than 2.0-fold between KR-62776- or rosiglitazone-treated adipocyte cells and control cells. Rosiglitazone down-regulated the expression of ERK1/2 and suppressed the phosphorylation of ERK1/2 in these cells. However, the expression of ERK1/2 was up-regulated in KR-62776-treated cells. Phosphorylated ERK1/2, activated by indenone, affects the localization of PPARγ, suggesting a mechanism for indenone-inhibition of adipogenesis in 3T3-L1 preadipocyte cells. The preadipocyte cells are treated with ERK1/2 inhibitor PD98059, a large amount of the cells are converted to adipocyte cells. These results support the conclusion that the localization of PPARγ is one of the key factors explaining the biological responses of the ligands.

Original languageEnglish
Pages (from-to)1766-1781
Number of pages16
JournalCellular and Molecular Life Sciences
Volume66
Issue number10
DOIs
StatePublished - May 2009

Keywords

  • Adipocyte
  • ERK
  • Indenone
  • Lipolysis
  • Peroxisome proliferators-activated receptor γ
  • Rosiglitazone

Fingerprint

Dive into the research topics of 'PPAR γ partial agonist, KR-62776, inhibits adipocyte differentiation via activation of ERK'. Together they form a unique fingerprint.

Cite this